2,6-二氯-4-甲基-3-氨基吡啶 | 129432-25-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,6-二氯-4-甲基-3-氨基吡啶
• 中文别名: 2,6-二氯-4-甲基吡啶-3-胺；2,6-二氯-3-氨基-4-甲基吡啶
• 英文名称: 2,6-dichloro-3-amino-4-methylpyridine
• 英文别名: 3-amino-2,6-dichloro-4-methylpyridine；2,6-dichloro-4-methylpyridin-3-amine；2,6-dichloro-4-methyl-3-aminopyridine
• CAS: 129432-25-3
• 化学式: C₆H₆Cl₂N₂
• mdl: MFCD01320814
• 分子量: 177.033
• InChiKey: AULKGEJDEAKINM-UHFFFAOYSA-N

物化性质

• 熔点：
  83.5-85.5 °C(Solv: benzene (71-43-2))
• 沸点：
  327.7±37.0 °C(Predicted)
• 密度：
  1.414±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 2-8°C |

反应信息

• 作为反应物：
  描述：

  2,6-二氯-4-甲基-3-氨基吡啶 在 sodium hydride 作用下， 以 various solvent(s) 为溶剂， 反应 5.0h， 生成 5,11-Dihydro-11-ethyl-2-(3-hydroxypropyl)amino-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
  参考文献：
  名称：

  Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzymes

  摘要：

  The major cause of viral resistance to the potent human immunodeficiency virus type 1 reverse transcriptase (RT) inhibitor nevirapine is the mutation substituting cysteine for tyrosine-181 in RT (Y181C RT), An evaluation, against Y181C RT, of previously described analogs of nevirapine revealed that the 2-chlorodipyridodiazepinone 16 is an effective inhibitor of this mutant enzyme. The detailed examination of the structure-activity relationship of 2-substituted dipyridodiazepinones presented below shows that combined activity against the wildtype and Y181C enzymes is achieved with aryl substituents at the 2-position of the tricyclic ring system. In addition, the substitution pattern at C-4, N-5, and N-11 of the dipyridodiazepinone ring system optimum for inhibition of both wild-type and Y181C RT is no longer the 4-methyl-11-cyclopropyl substitution preferred against the wild-type enzyme but rather the 5-methyl-11-ethyl (or 11-cyclopropyl) pattern. The more potent 8-substituted dipyridodiazepinones were evaluated against mutant RT enzymes (L100I RT, K103N RT, P236L RT, and E138K RT) that confer resistance to other non-nucleoside RT inhibitors, and compounds 42, 62, and 67, with pyrrolyl, aminophenyl, and aminopyridyl substituents, respectively, at the 2-position, were found to be effective inhibitors of these mutant enzymes also.

  DOI：

  10.1021/jm00024a010
• 作为产物：
  描述：

  3-氰基-4-甲基-2,6-二氯吡啶 在 sodium hydroxide 、 硫酸 、 溴 作用下， 生成 2,6-二氯-4-甲基-3-氨基吡啶
  参考文献：
  名称：

  Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzymes

  摘要：

  The major cause of viral resistance to the potent human immunodeficiency virus type 1 reverse transcriptase (RT) inhibitor nevirapine is the mutation substituting cysteine for tyrosine-181 in RT (Y181C RT), An evaluation, against Y181C RT, of previously described analogs of nevirapine revealed that the 2-chlorodipyridodiazepinone 16 is an effective inhibitor of this mutant enzyme. The detailed examination of the structure-activity relationship of 2-substituted dipyridodiazepinones presented below shows that combined activity against the wildtype and Y181C enzymes is achieved with aryl substituents at the 2-position of the tricyclic ring system. In addition, the substitution pattern at C-4, N-5, and N-11 of the dipyridodiazepinone ring system optimum for inhibition of both wild-type and Y181C RT is no longer the 4-methyl-11-cyclopropyl substitution preferred against the wild-type enzyme but rather the 5-methyl-11-ethyl (or 11-cyclopropyl) pattern. The more potent 8-substituted dipyridodiazepinones were evaluated against mutant RT enzymes (L100I RT, K103N RT, P236L RT, and E138K RT) that confer resistance to other non-nucleoside RT inhibitors, and compounds 42, 62, and 67, with pyrrolyl, aminophenyl, and aminopyridyl substituents, respectively, at the 2-position, were found to be effective inhibitors of these mutant enzymes also.

  DOI：

  10.1021/jm00024a010

文献信息

• 一种奈韦拉平中间体的制备方法
  申请人：湖北宇阳药业有限公司

  公开号：CN109096182A

  公开（公告）日：2018-12-28

  本发明提供了一种奈韦拉平中间体的制备方法，包括：取氨水、氰乙酸甲酯及双乙甲酯发生环合反应生成羟基物：2,6‑二羟基‑3‑氰基‑4‑甲基吡啶；滴加三乙胺，在该温度下通入氯气，至反应完全，得2,6‑二氯‑3‑氰基‑4‑甲基吡啶；投入浓硫酸，后升温至120℃反应3‑5h，后降温至60℃,加水进行水解反应，得2,6‑二氯‑3‑酰胺基‑4‑甲基吡啶；加降解试剂次氯酸钠经Hofmann反应，得到奈韦拉平中间体2,6‑二氯‑3‑氨基‑4‑甲基吡啶。本发明在氯化反应中，由通常用的三氯氧磷改为直接通氯气，解决了废水含量过高难处理，和三氯氧磷恶臭的气味问题，且产品一次性收率90.1％。
• [EN] CONTINUOUS ARYCYCLIC COMPOUND<br/>[FR] COMPOSÉ ARYCYCLIQUE CONTINU
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2012081736A1

  公开（公告）日：2012-06-21

  This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.

  这是为了提供一种具有DGAT1抑制活性的连续芳环化合物，用于预防和/或治疗由肥胖引起的肥胖或高脂血症、高三酸甘油酯血症、脂质代谢紊乱、脂肪肝、高血压、动脉硬化、糖尿病等，以及提供包含所述连续芳环化合物或其药学上可接受的盐的DGAT1抑制剂作为有效成分。所述连续芳环化合物由以下式表示：其中式中的取代基与规范中定义的相同，或其药学上可接受的盐。
• Dipyridodiazepinone derivatives; synthesis and anti HIV-1 activity
  作者：Nisachon Khunnawutmanotham、Nitirat Chimnoi、Arunee Thitithanyanont、Patchreenart Saparpakorn、Kiattawee Choowongkomon、Pornpan Pungpo、Supa Hannongbua、Supanna Techasakul

  DOI：10.3762/bjoc.5.36

  日期：——

  Ten dipyridodiazepinone derivatives were synthesized and evaluated for their anti HIV-1 reverse transcriptase activity against wild-type and mutant type enzymes, K103N and Y181C. Two of them were found to be promising inhibitors for HIV-1 RT.

  合成了十种二吡啶基二氮杂环己酮衍生物，并针对野生型和突变型酶K103N和Y181C评估它们对HIV-1逆转录酶的抑制活性。其中有两种被发现是有希望的HIV-1 RT抑制剂。
• Method for the preparation of 5,11-dihydro-6h-dipyrido
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US05571912A1

  公开（公告）日：1996-11-05

  This invention relates to a novel method for preparing certain dipyrido-diazepines.

  这项发明涉及一种制备特定二嘧啶-二氮杂环化合物的新方法。
• Non-nucleoside reverse transcriptase inhibitors
  申请人：——

  公开号：US20020028807A1

  公开（公告）日：2002-03-07

  Provided are compounds of the general formula I: 1 wherein R 2 is selected from the group consisting of H, F, Cl, (C 1-4 ) alkyl, (C 3-4 ) cycloalkyl and CF 3 ; R 4 is H or Me; R 5 is H, Me or Et, with the proviso that R 4 and R 5 are not both Me, and if R 4 is Me then R 5 cannot be Et; R 11 is Et, cyclopropyl, propyl, isopropyl, or isobutyl; and is selected from the group consisting of: 2 and pharmaceutically acceptable salts thereof, as inhibitors of HIV reverse transcriptase, wild-type and several mutant strains.

  提供的是一般式I的化合物：其中R2从H、F、Cl、(C1-4)烷基、(C3-4)环烷基和CF3组成的群体中选择；R4为H或Me；R5为H、Me或Et，但R4和R5不能同时为Me，如果R4为Me，则R5不能为Et；R11为Et、环丙基、丙基、异丙基或异丁基；并选择自以下组合物：2和其药学上可接受的盐，作为HIV逆转录酶、野生型和几种突变株的抑制剂。